Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

2 weeks ago Myeloma

Breaking Barriers: Equecabtagene Autoleucel Revives Hope for International RRMM Patients – Multiple Myeloma

Multiple Myeloma

Relapsed/refractory multiple myeloma (RRMM) presents a significant challenge worldwide, representing 13% of all blood cancers. Despite advances in treatment, many patients face poor outcomes and limited options. However, a groundbreaking CAR-T therapy, Equecabtagene Autoleucel, has recently demonstrated its life-changing potential in overcoming this medical impasse.

In February 2024, a 70-year-old patient from Kyrgyzstan, diagnosed with multiple myeloma 17 years ago, arrived at a Hospital of Chinese Xi’an seeking relief from severe pain and disease progression. The patient had undergone multiple treatments over the years, including chemotherapy and radiotherapy, but his condition continued to deteriorate with extensive bone destruction and kidney disease caused by the cancer.

Given the severity of his condition and the failure of previous treatments, he was selected for Equecabtagene Autoleucel therapy. After a series of preparatory treatments, the patient received CAR-T cell infusion in April 2024, and the results were remarkable. Within just one month, his myeloma cells were undetectable, and he achieved a complete response (CR) with no signs of minimal residual disease (MRD). The treatment was not only effective but also safe, with only mild side effects such as grade 1 cytokine release syndrome (CRS), which was easily managed.

This case exemplifies the transformative power of Equecabtagene Autoleucel, which has shown a 98.9% overall response rate (ORR) in clinical trials, with a CR rate of over 82%. It offers a beacon of hope for RRMM patients, particularly those who have exhausted conventional treatment options.

As one of China’s premier CAR-T therapies, Equecabtagene Autoleucel is breaking barriers, providing a new lease on life for patients globally. With its impressive safety profile and unparalleled efficacy, it is poised to play a pivotal role in extending survival and improving quality of life for those battling RRMM. This therapy is not only revolutionizing cancer treatment but also proving to be a lifeline for patients who previously faced limited options.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com

#MultipleMyeloma #CARTTherapy #CancerTreatment #MedicalInnovation #GlobalHealthcare #HopeForPatients #ChinaMedicalBreakthroughs #EquecabtageneAutoleucel #CAR_T #RRMM

2 weeks ago patient story

Celebrating Discharge: The Joy of a New Life/ Hope /Multiple myeloma

After a period of treatment, the Singaporean patient Teresa achieved remarkable results with CAR-T therapy at Jiahui International Hospital in Shanghai. Her condition reached complete remission (CR), and to celebrate this great news, the hospital held a brief yet heartwarming celebration for her.

In the celebratory photos, Teresa, along with Dr. Vicky Lee and her team of doctors and nurses, are all smiles, radiating the joy of victory. The photos not only captured this happiness but also served as a testament to the hard work and professionalism of the medical staff. Every member of Dr. Vicky Lee’s team is a true hero, using their expertise and selfless dedication to help Teresa overcome her illness.

Teresa, filled with emotion, said: “Although the treatment process was tough, I felt immense warmth and support from the doctors and nurses at Jiahui Hospital. Their professionalism and care gave me confidence, which ultimately led to such a successful outcome.”

On the day of her discharge, the medical staff extended their heartfelt blessings to Teresa. The nurses kindly reminded her of the precautions she needed to take after leaving the hospital, ensuring she could maintain good health during her recovery at home. Teresa expressed her gratitude to each member of the medical team, thanking them for the care and support they provided when she needed it most.

Standing at the hospital entrance, Teresa looked back on her treatment journey, filled with gratitude and hope. She knew that it was because of the selfless dedication and outstanding professionalism of these medical professionals that she could embrace health once again and look forward to a new chapter in life.

Teresa’s recovery story is not only a personal victory but also the result of the collective efforts of the entire medical staff at Jiahui Hospital. She is deeply grateful for their hard work and believes that many more patients will find new hope for recovery here in the future.

We will continue to follow the patient’s post-treatment progress and provide updates.

#CART #CARTTherapy #Hopeforpatients #FUCASO #Equecel #MultipleMyeloma #jihuiHospital #Shanghai #ChineseCart #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART #cancerfight #cancersurvivor #Jiahuihospital

2 weeks ago patient story

庆祝出院：新生的喜悦 /希望之路 /与癌症抗争 /希望 /CART/多发性骨髓瘤

###庆祝出院：新生的喜悦

经过一段时间的治疗，新加坡患者Teresa在上海嘉会国际医院的CAR-T治疗取得了令人振奋的成果。她的病情完全达到了完全缓解（CR），在这一喜讯的见证下，医院为她举行了一场简短而温馨的庆祝活动。

在庆祝合影中，Teresa与Dr. Vicky Lee及其团队的医生护士们笑容满面，洋溢着胜利的喜悦。照片不仅记录了这份喜悦，也见证了医护人员的辛勤付出和专业精神。Dr. Vicky Lee和团队的每一位成员都是真正的英雄，他们用专业知识和无私奉献帮助Teresa战胜了病魔。

Teresa感慨万千，她说：“这段时间的治疗过程虽然艰辛，但在嘉会医院医生和护士们的悉心照料下，我感受到了无比的温暖与支持。他们的专业和关怀让我充满了信心，最终取得了这样的好结果。”

出院那天，医护人员为Teresa送上了最真挚的祝福。护士们亲切地叮嘱她出院后的注意事项，确保她在回家后的康复过程中能够继续保持良好的健康状态。Teresa感激地与每一位医护人员道别，感谢他们在她最需要的时候给予的关爱和支持。

站在医院门口，Teresa回望这段治疗旅程，心中充满了感激和希望。她知道，正是因为有了这些无私奉献、专业卓越的医护人员，她才能重新拥抱健康，迎接新的生活。

Teresa的康复故事不仅是她个人的胜利，更是嘉会医院全体医护人员共同努力的成果。她深深感谢他们的辛勤付出，并相信未来将会有更多的患者在这里获得新生的希望。

我们将持续关注患者的治疗后续，并跟进报道。

1 month ago Hematological Neoplasms

Blood Cancer Solution Including leukemia, lymphoma, multiple myeloma, and others.

Blood Cancer Solution

Including leukemia, lymphoma, multiple myeloma, and others.

Blood Cancer

#leukemia #lymphoma #multiplemyeloma

#Hematologic malignancies are a group of malignant diseases originating from hematopoietic cells, often affecting the bone marrow, blood, and various organs and tissues throughout the body. Common types of hematologic malignancies include leukemia, myelodysplastic syndromes, lymphomas, multiple myeloma, and myeloproliferative neoplasms.

The causes of these diseases are complex, involving genetic mutations, immune abnormalities, radiation exposure, contact with harmful chemicals, infections, and hereditary factors. Additionally, poor lifestyle habits, high levels of stress, and environmental factors can also increase the risk of developing these conditions.

With an aging population and advancements in medical technology, the incidence of hematologic malignancies has been rising globally. In China, the incidence and mortality rates of leukemia and lymphoma are now among the top ranks of all malignancies.

However, hematologic malignancies are not incurable. In recent years, the treatment methods for these diseases have seen significant progress. From traditional combination chemotherapy and radiotherapy to hematopoietic stem cell transplantation, monoclonal antibody therapy, antibody-drug conjugates, small molecule targeted therapies, and the latest immunotherapies, treatment options have become increasingly diverse and precise.

Combination chemotherapy remains a primary treatment for many hematologic malignancies, despite its significant side effects. The efficacy of these treatments cannot be ignored. Modern chemotherapy regimens are continually being refined, including the incorporation of new cytotoxic drugs and targeted therapies, as well as the use of monoclonal antibodies. Additionally, the appropriate use of antiemetics, hematopoietic growth factors, and anti-infective agents helps to mitigate adverse effects.

Hematopoietic stem cell transplantation continues to be one of the most effective treatments for certain hematologic malignancies. The development of this treatment in China has been rapid, with 170 registered transplant centers by 2020.

Monoclonal antibodies, often referred to as “biological missiles,” have a high degree of specificity and single biological activity. They have revolutionized the treatment of hematologic malignancies. Antibody-drug conjugates (ADCs) utilize monoclonal antibodies to accurately identify tumor cell markers, guiding the delivery of chemotherapy drugs for targeted treatment.

Small molecule targeted therapies work by interfering with specific genes or proteins to inhibit tumor cell growth and proliferation. Gleevec, the first small molecule targeted therapy, increased the five-year survival rate for chronic myeloid leukemia (CML) patients from 30% to 89%, marking a breakthrough in cancer treatment. Today, there are numerous small molecule targeted drugs available for the treatment of hematologic malignancies, including BCR-ABL inhibitors, BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, and XPO1 inhibitors, with many more drugs currently in clinical trials expected to become available soon.

Immunotherapy includes immune checkpoint inhibitors (such as PD-1/L1), cancer vaccines, cellular immunotherapies (such as #CART), and nonspecific immunomodulatory treatments. #CARTtherapy, in particular, has gained widespread attention as an emerging curative treatment. This approach involves extracting a patient’s T cells, modifying them outside the body to specifically recognize and attack tumor cells, and then reinfusing the modified T cells into the patient. This therapy has been successfully applied to various hematologic malignancies, including acute lymphoblastic leukemia, lymphomas, and multiple myeloma. The first patient treated with CAR-T therapy has been disease-free for 11 years.

In recent years, China has made significant advances in the treatment of hematologic malignancies. The establishment of the “Chinese Expert Consensus on the Diagnosis and Treatment of High-Risk Multiple Myeloma” and the presentation by Professor Huang He at the 2024 #EHA conference on targeting CD7 universal CAR-T therapy for T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) have shown remarkable efficacy and safety. Additionally, exciting new data from the 2024 American Society of Clinical Oncology (#ASCO) annual meeting highlighted the efficacy of Relma-cel in treating relapsed/refractory large B-cell lymphoma (R/R LBCL), with a four-year overall survival rate (#OS) of 66.7%. Particularly noteworthy is the research on multiple myeloma, where the BCMA-targeted CAR-T therapy has demonstrated deep and lasting responses, with a complete response (#CR) rate of 82.4% and a 12-month progression-free survival (#PFS) rate of 85.5%.

With the continuous development of new treatments and the emergence of new drugs, hematologic malignancies in China are no longer considered incurable diseases. Through standardized, individualized, and precise treatments, many patients with hematologic malignancies can achieve long-term disease-free survival, and even a cure, returning to normal work and life. As medicine continues to advance, every life will continue to shine brightly!

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#HematologicMalignancies #LeukemiaAwareness #LymphomaResearch #MultipleMyeloma #BloodCancer #CancerResearch #CAR_Therapy #StemCellTransplant #Immunotherapy #TargetedTherapy #MonoclonalAntibodies #CancerTreatment #MedicalAdvancements #CancerSurvivor #HealthcareInnovation

1 month ago patient story

Light of Hope – The Starting Point for Multiple Myeloma Patients

### Light of Hope – The Starting Point for Multiple Myeloma Patients

Ms. Teresa sat in the comfortable seat of the apheresis room, watching the nurse gently insert the needle into her arm to draw the precious white blood cell samples. These white blood cells would become the core material for CAR-T therapy, engineered and then reintroduced into her body to become a powerful force against cancer.

In the operating room, machines hummed softly, precisely separating the T cells from Teresa’s body. These cells, which had faithfully performed their duty of protecting her body, would now be re-educated to become a precise strike team against cancer cells. Teresa closed her eyes and silently prayed that this apheresis would infuse her body with the strength to drive the disease out of her life.

The apheresis process lasted several hours, with medical staff carefully monitoring each step to ensure enough high-quality cells were collected. The extraction of these cells was not only a technical challenge but also a stringent test of the medical team’s professional capabilities.

After the apheresis was completed, Teresa felt somewhat relieved. She knew this was just the first step in a long treatment journey, but it was also an important starting point filled with hope. In the apheresis room, she felt the warmth and professionalism of the medical team, which filled her with confidence and hope for the future treatment.

Back in her ward, Teresa gently closed her eyes as she lay on the bed. She pondered how the coming days would unfold, hoping that this apheresis would bring her the strength to overcome the disease and regain her health.

Apheresis, as the first step of the treatment journey, marked a new chapter in Teresa’s brave fight against cancer and ignited a flame of hope for her future recovery.

#ThePathOfHope #FightingCancer #JourneyOfCARTTherapy #TogetherWithTongji #FullyHumanCART #HopeWithFUCASO #EquecelApproval #HealthReborn #UnitedInPrayer #MultipleMyeloma

2 months ago CAR-T

Sustained 7-Month CR, Liver Extramedullary Disease Disappearance: Equecabtagene Autoleucel Brings High-Quality Survival Hope to Ultra-High-Risk RRMM Patients with Extramedullary Disease

### Sustained 7-Month CR, Liver Extramedullary Disease Disappearance: Equecabtagene Autoleucel Brings High-Quality Survival Hope to Ultra-High-Risk RRMM Patients with Extramedullary Disease

RRMM Patients

In December 2019, a man in his 50s was diagnosed with multiple myeloma (MM) at a hospital in Shenzhen, China. The patient had high-risk cytogenetic abnormalities (17p deletion) and underwent various treatments over more than three years, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and CD38 monoclonal antibodies. Despite these treatments, the patient experienced a second relapse. This relapse was characterized by a P53 gene mutation and liver extramedullary invasion, classifying it as an ultra-high-risk situation. Although the patient initially refused an autologous stem cell transplant (ASCT), he was eventually persuaded to collect sufficient stem cells. However, due to concerns about the side effects of high-dose chemotherapy, he opted for CAR-T therapy.

### Personalized Treatment: From ASCT to CAR-T Therapy

Under the care of Professor Chen’s team at the hospital, the patient was evaluated for CAR-T therapy. Despite the risks, he underwent the treatment and showed significant improvement. As of March 2024, he has maintained a complete response (CR) for seven months, with PET/CT scans indicating the disappearance of liver extramedullary disease.

#### Patient Background

– Age: 54

– Initial Symptoms: Back pain after exercise

– Diagnosis: Multiple Myeloma (IgA κ type, DS I A stage, ISS I stage, R-ISS II stage, mSMART high-risk)

### Treatment Journey

– 2019: Diagnosed with MM; high-risk cytogenetic abnormality (17p deletion)

– 2020-2022: Treated with PIs, IMiDs, and CD38 monoclonal antibodies

– Early 2023: Second relapse with P53 mutation and liver extramedullary disease

– July 2023: Stem cell collection for ASCT

– August 2023: Initiated CAR-T cell (Equecabtagene Autoleucel) therapy

– September 2023: Discharged with strict complete response (sCR)

– March 2024: PET/CT scan confirms sustained complete response (CR) with no liver lesions

### Breakthrough Results and Future Prospects

CAR-T therapy has emerged as a promising treatment for relapsed and refractory multiple myeloma (RRMM), especially for patients resistant to conventional therapies. This case highlights the importance of personalized treatment plans, considering disease factors, previous treatment outcomes, and patient preferences. Equecabtagene Autoleucel (IKEA-Lunsay) CAR-T therapy has given this high-risk patient a new lease on life and holds the potential to offer hope to many more MM patients in China.

By showcasing such success stories, we aim to raise awareness about the advancements in CAR-T therapy and its significant impact on improving the quality of life for MM patients. This breakthrough not only marks a significant achievement for the hospital but also signals a new era of hope for countless MM patients.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#MedicalBreakthrough #CARTTherapy #MultipleMyeloma #CancerTreatment #PatientSuccess #HealthcareInnovation #CancerResearch #MMTreatment #LifeSavingTherapies #MedicalAdvancements #HealthcareHeroes #InnovativeMedicine #CancerCare #HopeForMM #CancerAwareness

3 months ago Myeloma

Interpretation of Hot Topics Conerning Relapsed/Refractory Mutiple Myeloma Patients

Interpretation of Hot Topics Conerning Relapsed/Refractory Mutiple Myeloma Patients:

What other treatment options are available for patients with relapsed Multiple Myeloma?

How effective is the new drug treatment for the first relapse of Multiple Myeloma?

What treatment options are available for initial relapse of multiple myeloma?

What are the treatment goals for Relapsed/Refractory Multiple Myeloma (RRMM)?

What treatment strategy should be adopted for RRMM in order to achieve maximum relief?

For Relapsed/Refractory Multiple Myeloma, what are the Grades of Response?

Expert Introduction

👩‍🔬Zhuang Junling

Associate Chief Physician Department of Hematology

Peking Union Medical College Hospital

Published over 50 papers in journals such as Blood, Leukemia Research, and others.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#CART #Mutiplemyeloma #CARTtherapy #myeloma #leukemia #drug #RRMM #cancer #cancersurvivor #cancerpatient #bloodcancer #tumor #cartcell #cartcelltherapy #cancertreatment #advancedmedicineinchina #hematology

5 months ago patient story , Myeloma

🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈

cancer fight

🌟Mr. C from California, USA

It’s yet another heartening piece of news as Mr. C from California, USA, undergoes cross-border treatment at Jiangsu Province People’s Hospital in China, successfully overcoming multiple myeloma and embracing a new lease on life! After meticulous treatment spanning one and a half months, Mr. C, accompanied by his loved ones, has made a successful recovery and been discharged from the hospital, becoming the first American patient to be successfully treated with CAR-T cell therapy for multiple myeloma in China.

🌞New treatment method

Mr. C, a 56-year-old American who is passionate about sports, discovered he had multiple myeloma after sustaining sports-related injuries. Despite enduring several unsuccessful treatment attempts, he refused to give up and began seeking treatment opportunities worldwide. However, the exorbitant cost of treating multiple myeloma in the USA deterred him. After comparing prices and data of CAR-T therapy for multiple myeloma between the USA and China, he ultimately decided to explore the new treatment method at Jiangsu Province People’s Hospital.

🌤Upon arriving in China,

Mr. C not only received meticulous care from medical staff but also had the opportunity to explore the scenic beauty of cities such as Nanjing, Suzhou, and Hangzhou, experiencing the unique cultural charm of China. During the CAR-T cell therapy treatment process, Mr. C underwent a life-threatening cytokine storm, but with the emergency intervention of the medical team, he successfully weathered the storm. Today, he has recovered and been discharged from the hospital, though slightly fatigued, he is still filled with hope and gratitude.

🔥Hope and Courage

Although Mr. C’s treatment has concluded, follow-up work will continue, with the medical team maintaining contact with his family doctor to closely monitor treatment effectiveness and subsequent conditions. As medical personnel, they sincerely hope that this treatment will provide Mr. C with more opportunities for survival.

☀️Mr. C also expressed his desire to revisit China, specifically Nanjing, to visit the experts and nurses who treated him, and of course, to continue savoring Chinese cuisine. This journey of treatment across continents not only granted Mr. C a new lease on life but also showcased the unity and dedication of medical personnel from both China and the USA. May this touching story inspire more people and bring forth more hope and courage!

⭐️CAR-T therapy

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to:

💌: doctor.huang@globecancer.com
📞WhatsApp 137 1795 9070

✨The Medical Department will contact you as soon as receive the reports.

#CARTtherapy #LymphomaTreatment #CompleteRemission #MedicalAdvancements #CancerResearch #CARTProgress #HopeForPatients #SurvivingLymphoma #HealthcareInnovation #PatientStories #CancerCure #CARTSuccess #MedicalBreakthrough #ImprovingOutcomes #LymphomaAwareness #FightAgainstCancer #CARTJourney #MedicalMilestone #LongTermSurvival #BeatingCancer #lymphoma #cancerawareness

5 months ago patient story , CAR-T

Expert Perspective: Options for CAR-T Therapy in Thai Patients

🌈Expert Perspective: Options for CAR-T Therapy in Thai Patients🌈

🌺In the Hematology Department of Tongji Hospital in Shanghai, Director Li Ping provided a detailed overview of the condition and treatment journey of Ms. P, a middle-aged Thai patient with multiple myeloma. After undergoing multiple treatments and autologous hematopoietic stem cell transplants in Thailand, the patient experienced relapses, ultimately opting for CAR-T therapy in China. Director Li Ping explained that CAR-T therapy represents a significant breakthrough in the field of hematologic malignancies, offering remarkable efficacy for patients with multiple refractory recurrences. The fully humanized CAR-T therapy drug, FUCASO (Eque-cel), known for its low immunogenicity and long-term efficacy, has brought hope of cure to patients. Tongji Hospital’s rich experience and comprehensive management in CAR-T therapy ensure the safety and effectiveness of treatment, providing high-quality medical services to international patients.

🌼We will continue to follow up on the patient’s treatment progress and provide further updates.

#CARTTherapy #MultipleMyeloma #FUCASO #Equecel #TongjiHospital #Shanghai #MedicalInnovation #CancerTreatment #Hematology #PatientJourney #Immunotherapy #patientstory

5 months ago Myeloma

🩸 Breakthrough in Multiple Myeloma Treatment! 🩺

LANCET

🔬Targeting GPRC5D with CAR-T Cells shows immense potential in treating relapsed or refractory multiple myeloma patients.
Multiple myeloma, a malignant disease characterized by clonal plasma cell proliferation in the bone marrow, has remained incurable despite substantial progress in treatment methods such as systemic chemotherapy, radiation therapy, and hematopoietic stem cell transplantation (HSCT). However, CAR-T cell therapy targeting B-cell maturation antigen (BCMA) has demonstrated activity in treating relapsed or refractory multiple myeloma. Nonetheless, the escape of BCMA-low or BCMA-negative myeloma cells has led to treatment resistance and relapse, highlighting the need to explore new targets.

💪In February 2023, a groundbreaking study titled “GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-center, single-arm, phase 1 trial” was published in The Lancet Haematology. The study aimed to evaluate the activity and safety of G-protein-coupled receptor class 5 member D (GPRC5D) CAR-T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma.

🌈Promising Treatment Response with OriCAR-017 Infusion
All ten patients (100%) demonstrated an overall response, with 6 patients (60%) achieving a complete response and 4 patients (40%) showing very good partial responses. The patients with complete responses met stringent complete response criteria, and all patients achieved minimal residual disease (MRD) negativity by day 28. Serum M-protein concentrations gradually decreased, and patients’ clinical responses improved over time. The median time to the best response was 3.1 months, while the median time to a complete response or better was 4.1 months.

☀️Among the 5 patients who relapsed after BCMA CAR-T cell therapy, 2 patients achieved a stringent complete response, and 3 patients showed very good partial responses. Four patients had extramedullary disease at enrollment, with the largest tumor volume measuring 70 cm³. PET-CT scans revealed complete resolution of extramedullary lesions in three patients, while the extramedullary disease in one patient continued to shrink. Furthermore, no severe adverse events or treatment-related deaths were reported.

🌱Favorable Survival Outcomes after OriCAR-017 Infusion
⏰The median follow-up time for all patients was 238 days, with two patients progressing after achieving stringent complete remission. One patient experienced GPRC5D-positive relapse, with GPRC5D expression in malignant plasma cells increasing from 34.5% at baseline to 35.8% at relapse. The other patient experienced GPRC5D-negative relapse, with GPRC5D expression in malignant plasma cells decreasing from 86.8% at baseline to 6.9% at relapse. The remaining eight patients in ongoing remission were all negative for minimal residual disease, and no deaths occurred. The median progression-free survival time was not reached, but the estimated progression-free survival rate for all patients at nine months was 87.5%.

🧬Durable CAR-T Cell Persistence
✨CAR-T cell expansion was detected in all patients after infusion, with a median time to maximum CAR-T cell expansion (Cmax) of 10.0 days and a median Cmax of 7930 copies/μl. CAR-T cells exhibited favorable persistence in the body, with CAR-T cells still detectable in 90% of patients at one month, seven patients at three months, and four patients at six months.

🌟 The study results demonstrate that targeting GPRC5D with CAR-T cells in treating relapsed or refractory multiple myeloma patients is safe and shows promising activity. The observed targeted and off-target toxicities associated with GPRC5D were manageable, indicating the potential of GPRC5D as an effective immunotherapeutic target for multiple myeloma. These findings provide a foundation for subsequent phase 2 studies to further validate the efficacy and safety of targeting GPRC5D CAR-T cells in multiple myeloma.🦾

We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.
We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.
doctor.huang@globecancer.com
WhatsApp+8613717959070

🔬 Stay tuned for more updates on this groundbreaking research! Together, we can conquer multiple myeloma!

#MultipleMyelomaResearch #CARTTherapy #GPRC5D #MedicalBreakthrough #cart #multiplemyeloma #chinesecart #cartcell #carttherapy #LANCET #Haematology #CARTCell

6 months ago CAR-T

China’s another cancer center launches an international medical department, offering comprehensive one-stop medical services to overseas patients

China’s another cancer center launches an international medical department, offering comprehensive one-stop medical services to overseas patients.

cancer center

The International Medical Department of Tongji Hospital,

affiliated with Tongji University in Shanghai, has recently been officially launched. The department focuses on providing international medical services and aims to offer overseas patients a one-stop, seamless medical experience with high-quality and convenient healthcare services.

The advantages

of the International Medical Department at Tongji Hospital go beyond providing one-stop, comprehensive medical services to overseas patients. It also means that overseas patients can receive a full range of medical services, from initial consultation to treatment and recovery, all in one place, without the need for frequent referrals or seeking treatment across multiple hospitals. The department is equipped with advanced facilities and equipment, including PET-CT scanners, linear accelerators (LA), high-end MRI and CT scanners, DSA machines, as well as integrated hybrid operating rooms, laparoscopic surgery systems, and 4K3D high-definition laparoscopes, providing patients with state-of-the-art diagnostic and treatment methods.

Furthermore, as another cancer center in China

it offers the most advanced CAR-T cell therapy globally to all overseas patients. Tongji Hospital, well-known for its cancer treatment expertise in China, has accumulated rich experience and professional knowledge in the field of

CAR-T cell therapy

, enabling them to provide personalized and customized medical solutions for patients. The International Medical Department primarily serves high-end commercial insurance clients, foreign patients, overseas Chinese, diplomats and their families, and international corporate employees. The services provided by the department include initial consultation assessments, disease diagnosis, treatment plan development, surgeries and interventional therapies, rehabilitation, and follow-up care.

The medical team

is the core strength of the department. The International Medical Department at Tongji Hospital has recruited a team of foreign physicians, clinical experts, and returning young doctors from Tongji Hospital, covering almost all clinical specialties. In addition, the department regularly invites internationally renowned experts to visit, such as Professor Kurt Fritzsch, a professor of psychosomatic medicine at the University of Freiburg in Germany, and Professor Claus Cursiefen, a professor of ophthalmology at the University of Cologne in Germany. Especially as a cancer center in China, Tongji Hospital also has a team with the highest number of CAR-T cancer treatment cases worldwide, ensuring the provision of top-quality medical services to patients.

If patients are interested in seeking treatment in China

and staying at the International Medical Department of Tongji Hospital in Shanghai, or if they want to inquire about China’s cancer centers and the highest level of CAR-T therapy worldwide, the team at “Advanced medicine in China” will provide all the relevant services. These services include, but are not limited to, expert evaluations, online consultations with specialists, insurance service consultations, multilingual accompanying services, multilingual medical consultations and translation services, disease diagnosis, customized treatment plans, surgeries, interventional therapies, CAR-T treatments, hospitalization services, emergency rescue, referral services, medical companions, services for accompanying family members, and post-recovery guidance, among other value-added services, fully meeting the needs of patients.

Menu

Tags Archives: CART Therapy